Publicador de contenidos

Investigación e Innovación Programas
Resistencia antimicrobiana

Development of new metal-antibiotics against pathogens causing chronic infections in patients with cystic fibrosis.

New metal-antibiotics for patients with cystic fibrosis

Duración
01/01/2017 - 31/12/2019
Coordinador
Sara M. Soto
Financiadores
Instituto de Salud Carlos III (ISCIII)

Airways infection remains the leading cause of morbidity and mortality, estimated at 85% in patients with cystic fibrosis (CF).

Methicillin Resistant Staphylococcus aureus (MRSA), Haemophilus influenzae, Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia and non-tuberculosis mycobacteriae, are the main microorganisms involved in these infections. Respiratory microbiota of a CF patient is exposed to a strong antibiotic pressure due to frequent and prolonged treatments, leading to the emergence of antimicrobial resistance and the selection of highly resistant strains.

The main objective of this project is the research and development of functional gold complexes (metalantibiotcs) that are active against these microorganisms both in planktonic state and growing in biofilms. To do this, phenotypic methods directed to microbiological analysis of antomicrobial resistance (antibiogram), the analysis of resistance of biofilms (antibiofilmogram), the study of susceptibility against combinations of metalantibiotcs/conventional antibiotics, chemical methods for metalantibiotcs synthesis and development, as well as molecular methods such as genomics, will be used.

Total funding

157,602 €

Nuestro equipo

PI

  • Sara Soto Gonzalez
    Sara Soto Gonzalez

Team

  • Yuly De Los Angeles López Cubillos
    Yuly De Los Angeles López Cubillos
  • GRISELDA TUDO
    GRISELDA TUDO Associated Researcher

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias